Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.37 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | GLS | O94925 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976803 | 0.94 | EPAS1 (0.42) | EPAS1BAZ1ATP53GLSLMNA | |
| SCHEMBL2976797 | 0.94 | EPAS1 (0.42) | EPAS1BAZ1ATP53GLSLMNA | |
| SCHEMBL2978873 | 0.94 | EPAS1 (0.42) | EPAS1BAZ1ATP53GLSLMNA | |
| SCHEMBL2973766 | 0.87 | EPAS1 (0.40) | EPAS1BAZ1ATP53GLSACHE | |
| SCHEMBL2973773 | 0.87 | EPAS1 (0.40) | EPAS1BAZ1ATP53GLSACHE | |
| SCHEMBL2973095 | 0.82 | TACR1 (0.45) | EPHX2EPAS1TP53KMT2ASIRT5 | |
| SCHEMBL2973091 | 0.82 | TACR1 (0.45) | EPHX2EPAS1TP53KMT2ASIRT5 | |
| SCHEMBL2977282 | 0.78 | CTSL (0.42) | EPAS1TP53KMT2ALMNARXFP1 | |
| SCHEMBL2975871 | 0.78 | EPAS1 (0.39) | EPAS1TP53LMNAMAPTACHE | |
| SCHEMBL2975877 | 0.78 | EPAS1 (0.39) | EPAS1TP53LMNAMAPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | HAVCR2, ZC3HAV1, MAVS | EPHX2 3359/4885EPAS1 917/4885BAZ1A 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.